Endovascular Today
VerifiedMagazine
Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurointerventionists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.
Endovascular Today is published 12 times per year and also offers a free biweekly eNewsletter, advising of recent FDA approvals, clinical trial updates, Medicare coverage news, and new product launches. Please visit our subscriptions page for more information on receiving Endovascular Today.
Actions
Media Outlet details
| Scope | Trade/B2B, Consumer |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesJupiter Endovascular Appoints Dr. Catalin Toma as Chief Medical Officer
KEY TAKEAWAYS Jupiter Endovascular appointed interventional cardiologist Catalin Toma, MD, as Chief Medical Officer,a newly created global role. Dr. Toma was a Global Coprincipal Investigator of SPIRARE II pivotal trial evaluating the Vertex thrombectomy system in acute, intermediate-risk pulmonary embolism. Dr. Toma will bring clinical and research experience in pulmonary vascular, structural heart, and interventional cardiovascular medicine to the company.
Vesalio’s pVasc Net Mechanical Thrombectomy Device Receives FDA 510(k) Clearance
KEY TAKEAWAYS The FDA granted 510(k) clearance to Vesalio’s pVasc Net peripheral mechanical thrombectomy device. The device incorporates a fine-pore, dual-layer distal filter intended to capture clot fragments during retrieval. pVasc Net builds on Vesalio’s pVasc platform and supports radiopaque visualization and an aspiration-compatible workflow.
ARPA-H Funding Will Support Teams to Advance Robotics Stroke Interventions
KEY TAKEAWAYS ARPA-H awarded contracts to seven teams developing autonomous robotic systems and microbots for stroke and other interventions. The AIR program includes up to $175.3 million in agency funding over 5 years, with individual awards tied to research milestones. Teams are expected to demonstrate autonomous capabilities at 24 months and fully autonomous interventions at 60 months.
FastWave’s SPARC Pivotal Trial of Artero Peripheral IVL System Receives IDE Approval
KEY TAKEAWAYS FDA approved FastWave Medical’s IDE for the United States pivotal trial of the Artero peripheral IVL system. SPARC will evaluate the safety and effectiveness of the device in up to 125 patients with calcified peripheral lesions at 30 investigational sites. Sahil Parikh, MD, and Venita Chandra, MD, will serve as Coprincipal Investigators of the pivotal study.
Penumbra Appoints Dr. Donald Frei as Associate Chief Medical Officer of Neuro
KEY TAKEAWAYS Donald Frei, MD, has joined Penumbra as Associate Chief Medical Officer of Neuro. Dr. Frei will help guide the company’s neurovascular clinical strategy, evidence development, and physician collaboration. He served as Coprincipal Investigator of THUNDER, which supported recent United States and European regulatory approvals for Penumbra’s Thunderbolt CAVT platform. August 11, 2026—Penumbra announced today that Donald Frei, MD, will serve as Associate Chief Medical Officer of Neuro.
Vexev Raises Funds to Support VxWave Autonomous Vascular Imaging Platform
KEY TAKEAWAYS Vexev raised $6 million in new funding to advance FDA 510(k) clearance and United States commercialization of its VxWave robotic tomographic ultrasound platform. The financing brings the company’s total funding to $19 million. In the CANSCAN feasibility trial, VxWave achieved a 94% scanning success rate for autonomous vascular imaging by nonspecialist clinical staff.
Fluidx Medical Closes Financing to Advance Next-Generation Embolic Platforms
KEY TAKEAWAYS Fluidx Medical closes financing to support development and commercialization activities for its GPX, Ultra, and Impass embolic technologies. The funding will support manufacturing and commercial readiness for GPX and Ultra and further development of the investigational Impass neurovascular technology. The financing comes after completion of the GPX investigational device exemption clinical trial and submission of the final module of its premarket approval application to the FDA.
Salus Scientific Closes Series A Financing to Support Occupational Wellness Platform
KEY TAKEAWAYS Salus Scientific closes an oversubscribed Series A financing, raising $10.1 million. Proceeds will support commercial expansion, increased production capacity, clinical infrastructure, and its planned revenue ramp. Salus Scientific develops occupational wellness technologies, including radiation protection garments and workflow solutions for fluoroscopy-guided procedures.
ALARA+ Coalition Launches Toolkits to Accelerate Adoption of Enhanced Radiation Protection
KEY TAKEAWAYS The ALARA+ Coalition has released four implementation toolkits designed to help hospitals adopt enhanced radiation protection devices and occupational safety practices in catheterization laboratories. The resources translate recently published multisociety guidance into practical tools for hospital leadership, catheterization laboratory teams, and policymakers.
Funding Will Advance Xeltis’ aXess Device United States Regulatory and Commercial Pathway
KEY TAKEAWAYS Xeltis has raised an additional €20.5 million to support regulatory, clinical, and commercial activities for its aXess vascular access device. The financing will help complete the ongoing United States pivotal trial of aXess, which the company said has surpassed 50% enrollment. The funding will also support European commercialization of aXess, manufacturing scale-up, and continued development of the company’s peripheral and coronary vascular programs.